Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873565 | 0.80 | — | — | |
| SCHEMBL14672239 | 0.79 | TSHR (0.35) | TSHRPIK3CDRIPK1HDAC3HDAC1 | |
| SCHEMBL9386 | 0.78 | — | — | |
| SCHEMBL28050407 | 0.77 | — | — | |
| SCHEMBL28040988 | 0.77 | — | — | |
| SCHEMBL29754604 | 0.77 | CES2 (0.36) | CES2CES1TSHRPIK3CDHDAC3 | |
| SCHEMBL15751185 | 0.77 | TSHR (0.34) | TSHRPIK3CDRIPK1HDAC3HDAC1 | |
| SCHEMBL13751193 | 0.77 | PIK3CD (0.37) | CES2CES1TSHRPIK3CD | |
| Hydrochloric Acid SCHEMBL2028850 | 0.76 | TSHR (0.50) | TSHRPIK3CDRIPK1HDAC3HDAC1 | |
| SCHEMBL29234252 | 0.76 | TSHR (0.50) | TSHRPIK3CDRIPK1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160319312-A1 | SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| US-20160319312-A1 | SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-7579487-B2 | Process for making N-sulfonated-amino acid derivatives | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579487-B2 | Process for making N-sulfonated-amino acid derivatives | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| WO-2009077186-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESLLSCHAFT (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070909-A1 | Non-steroidal progesterone receptor modulators | Bayer Schering Pharma AG (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20070219382-A1 | Process For Making N-Sulfonated-Amino Acid Derivatives | MERCK SHARP & DOHME CORP. | 2007-09-20 | — | — | US | disclosed |
| US-20070219382-A1 | Process For Making N-Sulfonated-Amino Acid Derivatives | MERCK SHARP & DOHME CORP. | 2007-09-20 | — | — | US | disclosed |
| JP-2006249005-A | METHOD FOR PRODUCING 2-(TETRAHYDROPYRAN-4-YL)-2-OXOACETIC ACID | UBE IND LTD | 2006-09-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | CES2 4709/4885CES1 1361/4885TSHR 121/4885 |
| US-20070219382-A1 | Process For Making N-Sulfonated-Amino Acid Derivatives | ANTXR2, STS, ASNS | CES2 3353/4885CES1 772/4885TSHR 3345/4885 |
| US-20160319312-A1 | SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF | ADH1B, BCAT2, BCAT1 | CES2 1614/4885CES1 269/4885TSHR 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.